Ningetinib exhibited good therapeutic effects on FLT3 mutant AML models in vitro, and showed significant antitumor effects in MOLM13-, Ba/F3-FLT3-ITD-, Ba/F3-FLT3-ITD-F691L- and MOLM13-FLT3-ITD-F691L-driven leukemia mouse models, with results superior to existing clinical drugs gilteritinib and quizartinib. This evidence concerns the gene FLT3 and acute myeloid leukemia.